Press Release: Amarex Clinical Research : Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis

Amarex Clinical Research, LLC Guides Its Client to Phase II of FDA Trials GERMANTOWN, Md., June 9, 2022 /PRNewswire/ -- Amytrx and Amarex Clinical Research, LLC, an NSF company, today announced they are initiating the Phase II clinical trial on atopic dermatitis (AD) using Amytrx's...